Carmell Therapeutics plans to acquire Arizona biotech firm for $65M


Carmell Therapeutics Corp. said it plans to have Axolotl Biologix operate as a wholly-owned subsidiary of Carmell should the deal meet regulatory approvals and other conditions.

Previous Advent Therapeutics lands $3M NIH grant to advance therapy to benefit premature infants
Next Former CEO pleads guilty to lying to feds during $40M health care fraud investigation